Ten-Year relative survival and causes of death in elderly patients treated with R-CHOP or CHOP in the GELA LNH-985 trial

Clinical Lymphoma, Myeloma and Leukemia

Volumn 12, Issue 3, 2012, Pages 151-154

  Mounier, Nicolas ^a   Heutte, Natacha ^b   Thieblemont, Catherine ^c   Briere, Josette ^c   Gaulard, Philippe ^d   Feugier, Pierre ^e   Ghesquieres, Hervé ^f   Van Den Neste, Eric ^g   Robu, Daniela ^h   Tilly, Herve ⁱ   Bouabdallah, Reda ^j   Safar, Violaine ^d   Coiffier, Bertrand ^k  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b UNIVERSITÉ DE CAEN   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e UNIVERSITY HOSPITAL OF NANCY   (France)

^f CENTRE LÉON BÉRARD   (France)

^g UCL Saint Luc   (Belgium)

^h Department of Hematology   (France)

ⁱ CENTRE HENRI BECQUEREL   (France)

^j INSTITUT PAOLI CALMETTES   (France)

^k CENTRE HOSPITALIER LYON SUD   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

BLADDER CANCER; CANCER GROWTH; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COMPARATIVE STUDY; ESOPHAGUS CANCER; FOLLOW UP; GERIATRIC PATIENT; HUMAN; KIDNEY CANCER; LARGE CELL LYMPHOMA; LIVER CANCER; LUNG CANCER; LYMPHOMA; MORTALITY; MYELODYSPLASTIC SYNDROME; NOTE; OVERALL SURVIVAL; PROSTATE CANCER; SURVIVAL; TONGUE CANCER; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAUSE OF DEATH; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; VINCRISTINE;

EID: 84861032488     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.11.004     Document Type: Note

References (16)

1. M. Pfreundschuh, J. Schubert, M. Ziepert Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) Lancet Oncol 9 2008 105 116
2. B. Coiffier, C. Thieblemont, E. Van Den Neste Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte Blood 116 2010 2040 2045
3. P.W. Dickman, A. Sloggett, M. Hills Regression models for relative survival Stat Med 23 2004 51 64 (Pubitemid 38072106)
4. B. Coiffier, E. Lepage, J. Briere CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 2002 235 242 (Pubitemid 34438862)
5. P. Feugier, A. Van Hoof, C. Sebban Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 23 2005 4117 4126 (Pubitemid 46211317)
6. Institut National de la Statistique et des études économiques http://www.insee.fr/fr/themes/detail.asp?ref-id= irsd2006&page=irweb/sd2006/dd/sd2006-mortalite.htm Accessed December 21, 2011
7. M. Pirani, R. Marcheselli, L. Marcheselli Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis Ann Oncol 22 2011 1845 1858
8. A.K. Ng, A. Lacasce, L.B. Travis Long-term complications of lymphoma and its treatment J Clin Oncol 29 2011 1885 1892
9. M. Andre, N. Mounier, X. Leleu Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients Blood 103 2004 1222 1228 (Pubitemid 38168631)
10. E.C. Moser, E.M. Noordijk, F.E. van Leeuwen Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study Haematologica 91 2006 1481 1488 (Pubitemid 44736114)
11. S. Sacchi, L. Marcheselli, A. Bari Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study Haematologica 93 2008 1335 1342
12. N.Y. Mudie, A.J. Swerdlow, C.D. Higgins Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study J Clin Oncol 24 2006 1568 1574 (Pubitemid 46638780)
13. C. Tarella, R. Passera, M. Magni Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma J Clin Oncol 29 2011 814 824
14. L.M. Morton, R.E. Curtis, M.S. Linet Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype J Clin Oncol 28 2010 4935 4944
15. E.C. Moser, E.M. Noordijk, F.E. van Leeuwen Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma Blood 107 2006 2912 2919
16. M. Aapro, C. Bernard-Marty, E.G. Brain Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper Ann Oncol 22 2011 257 267